Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat ITP
The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in patients with previously treated immune thrombocytopenia.
Medscape Medical News
source https://www.medscape.com/viewarticle/rilzabrutinib-shines-phase-3-trial-tough-treat-immune-2024a1000mlv?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/rilzabrutinib-shines-phase-3-trial-tough-treat-immune-2024a1000mlv?src=rss
Comments
Post a Comment